FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377015867> ?p ?o ?g. }

• W4377015867 endingPage "S383" @default.
• W4377015867 startingPage "S383" @default.
• W4377015867 abstract "Patients with atrial fibrillation (AF) that suffer from ischemic stroke despite oral anticoagulant (OAC) therapy have a very high risk of recurrent stroke and better prevention strategies are needed. Left atrial appendage occlusion (LAAO) is a promising secondary prevention strategy that may provide mechanical protection. However, evidence showing effectiveness of LAAO in this population is scarce and the current international guidelines only consider LAAO in patients with a contra-indication for OAC. To compare percutaneous LAAO to standard-of-care including continuing/switching OAC therapy for secondary stroke prevention in patients with AF and a prior thrombo-embolic event and/or LAA thrombus under OAC therapy. The STR-OAC LAAO cohort is an international collaboration of multiple LAAO registries (21 participating centers). All patients that underwent percutaneous LAAO because of a thrombo-embolic event and/or LAA thrombus on OAC were included. Propensity score matching with a previously published multi-center dataset of patients continuing/switching OAC therapy after a thrombo-embolic event was performed to compare the occurence of ischemic stroke between groups.Time-to-event analysis was performed with Kaplan-Meier curves and Cox-proportional-hazard regression analyses. A total of 425 patients underwent LAAO between 2010-2021 and were included in the STR-OAC LAAO cohort. Mean age was 72±9 years; 45% was female and mean CHA2DS2-VASc and HAS-BLED score were 4.8±1.5 and 2.8±1.2, respectively. Oral anticoagulation was discontinued after LAAO at discharge or after confirmation of adequate LAA closure at 1-3 months follow-up in most patients, the remaining 30% of patients continued OAC after LAAO as an adjunctive strategy. All LAAO patients were propensity-score matched and included in the primary outcome analysis. During follow up including 1450 patient-years a total of 59 patients experienced ischemic stroke: 1.9% per patient-year in LAAO group versus 9.2% per patient-year in the control group. LAAO was associated with a significantly lower risk of ischemic stroke (HR 0.3, 95%CI [0.2-0.5], p<0.001) compared to standard-of-care. In this propensity-score matched study, LAAO was associated with a lower risk of ischemic stroke compared to standard-of-care in patients with a thrombo-embolic event and/or LAA thrombus despite OAC treatment. Randomized controlled trial data may further confirm the effectiveness of LAAO in this very high-risk population." @default.
• W4377015867 created "2023-05-19" @default.
• W4377015867 creator A5006124487 @default.
• W4377015867 creator A5007005929 @default.
• W4377015867 creator A5008139787 @default.
• W4377015867 creator A5009796795 @default.
• W4377015867 creator A5015896567 @default.
• W4377015867 creator A5018719607 @default.
• W4377015867 creator A5019009414 @default.
• W4377015867 creator A5020242367 @default.
• W4377015867 creator A5021676352 @default.
• W4377015867 creator A5021936215 @default.
• W4377015867 creator A5025700014 @default.
• W4377015867 creator A5026057493 @default.
• W4377015867 creator A5029765789 @default.
• W4377015867 creator A5033347468 @default.
• W4377015867 creator A5036024315 @default.
• W4377015867 creator A5036824107 @default.
• W4377015867 creator A5037854769 @default.
• W4377015867 creator A5039321258 @default.
• W4377015867 creator A5045801241 @default.
• W4377015867 creator A5047243715 @default.
• W4377015867 creator A5051526386 @default.
• W4377015867 creator A5053858541 @default.
• W4377015867 creator A5055447547 @default.
• W4377015867 creator A5057373053 @default.
• W4377015867 creator A5058448512 @default.
• W4377015867 creator A5062171901 @default.
• W4377015867 creator A5064037921 @default.
• W4377015867 creator A5064995734 @default.
• W4377015867 creator A5067607910 @default.
• W4377015867 creator A5068136057 @default.
• W4377015867 creator A5071947530 @default.
• W4377015867 creator A5072957878 @default.
• W4377015867 creator A5076072571 @default.
• W4377015867 creator A5076156498 @default.
• W4377015867 creator A5077862640 @default.
• W4377015867 creator A5078024797 @default.
• W4377015867 creator A5078586706 @default.
• W4377015867 creator A5079402460 @default.
• W4377015867 creator A5083906814 @default.
• W4377015867 creator A5088937468 @default.
• W4377015867 creator A5090799220 @default.
• W4377015867 creator A5083020549 @default.
• W4377015867 date "2023-05-01" @default.
• W4377015867 modified "2023-10-18" @default.
• W4377015867 title "PO-03-135 LEFT ATRIAL APPENDAGE OCCLUSION VERSUS STANDARD OF CARE IN PATIENTS WITH ATRIAL FIBRILLATION AND A PRIOR THROMBO-EMBOLIC EVENT DESPITE ORAL ANTICOAGULANT THERAPY: A PROPENSITY SCORE MATCHED COMPARISON" @default.
• W4377015867 doi "https://doi.org/10.1016/j.hrthm.2023.03.873" @default.
• W4377015867 hasPublicationYear "2023" @default.
• W4377015867 type Work @default.
• W4377015867 citedByCount "0" @default.
• W4377015867 crossrefType "journal-article" @default.
• W4377015867 hasAuthorship W4377015867A5006124487 @default.
• W4377015867 hasAuthorship W4377015867A5007005929 @default.
• W4377015867 hasAuthorship W4377015867A5008139787 @default.
• W4377015867 hasAuthorship W4377015867A5009796795 @default.
• W4377015867 hasAuthorship W4377015867A5015896567 @default.
• W4377015867 hasAuthorship W4377015867A5018719607 @default.
• W4377015867 hasAuthorship W4377015867A5019009414 @default.
• W4377015867 hasAuthorship W4377015867A5020242367 @default.
• W4377015867 hasAuthorship W4377015867A5021676352 @default.
• W4377015867 hasAuthorship W4377015867A5021936215 @default.
• W4377015867 hasAuthorship W4377015867A5025700014 @default.
• W4377015867 hasAuthorship W4377015867A5026057493 @default.
• W4377015867 hasAuthorship W4377015867A5029765789 @default.
• W4377015867 hasAuthorship W4377015867A5033347468 @default.
• W4377015867 hasAuthorship W4377015867A5036024315 @default.
• W4377015867 hasAuthorship W4377015867A5036824107 @default.
• W4377015867 hasAuthorship W4377015867A5037854769 @default.
• W4377015867 hasAuthorship W4377015867A5039321258 @default.
• W4377015867 hasAuthorship W4377015867A5045801241 @default.
• W4377015867 hasAuthorship W4377015867A5047243715 @default.
• W4377015867 hasAuthorship W4377015867A5051526386 @default.
• W4377015867 hasAuthorship W4377015867A5053858541 @default.
• W4377015867 hasAuthorship W4377015867A5055447547 @default.
• W4377015867 hasAuthorship W4377015867A5057373053 @default.
• W4377015867 hasAuthorship W4377015867A5058448512 @default.
• W4377015867 hasAuthorship W4377015867A5062171901 @default.
• W4377015867 hasAuthorship W4377015867A5064037921 @default.
• W4377015867 hasAuthorship W4377015867A5064995734 @default.
• W4377015867 hasAuthorship W4377015867A5067607910 @default.
• W4377015867 hasAuthorship W4377015867A5068136057 @default.
• W4377015867 hasAuthorship W4377015867A5071947530 @default.
• W4377015867 hasAuthorship W4377015867A5072957878 @default.
• W4377015867 hasAuthorship W4377015867A5076072571 @default.
• W4377015867 hasAuthorship W4377015867A5076156498 @default.
• W4377015867 hasAuthorship W4377015867A5077862640 @default.
• W4377015867 hasAuthorship W4377015867A5078024797 @default.
• W4377015867 hasAuthorship W4377015867A5078586706 @default.
• W4377015867 hasAuthorship W4377015867A5079402460 @default.
• W4377015867 hasAuthorship W4377015867A5083020549 @default.
• W4377015867 hasAuthorship W4377015867A5083906814 @default.
• W4377015867 hasAuthorship W4377015867A5088937468 @default.
• W4377015867 hasAuthorship W4377015867A5090799220 @default.
• W4377015867 hasBestOaLocation W43770158671 @default.
• W4377015867 hasConcept C126322002 @default.
• W4377015867 hasConcept C127413603 @default.
• W4377015867 hasConcept C141071460 @default.

• next